All In Biotech

Drug Trial Radar · NCT07840365

Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion

Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion (INTEGRAL)

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

234

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Dec 15, 2028

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Texas Cardiac Arrhythmia Research FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized study was designed to compare two antithrombotic regimens (long-term half-dose apixaban vs long-term aspirin after 45-days of full-dose apixaban) after successful Watchman implantation.

Conditions

  • Atrial Fibrillation (AF)

Interventions

  • Half-Dose of novel OACDrug

    Patients randomized to long-term half-dose apixaban (Group hdNOAC) will receive half-dose (2.5mg BID) apixaban monotherapy throughout the study period

  • Low-dose ASADrug

    In the low-dose ASA group, patients will receive full-dose of apixaban for 45 days followed by the low-dose aspirin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite endpoint of DRT, TE and major bleeding eventsTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Texas Cardiac Arrhythmia Institute, St. David's Medical Center

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.